Differentiated thyroid cancer is a frequent diagnosis and includes malignancies with diverse clinical behavior.
Although overall prognosis is excellent, treatment carries substantial morbidity risks.
Stratification of risk, based on pathology, tumor biology, ongoing biochemical and imaging assessments, and patient comorbidities, now forms the essential basis of DTC management with an imperative to provide care that is individualized and disease appropriate.